Pluristem Therapeutics Inc.
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Pluristem Therapeutics Inc.
Public Company Edition: ORIC’s initial public offering is the third by a drug developer in April and the 12th in 2020. Also, Pluristem garnered €50m from the European Investment Bank.
A new COVID-19 vaccine dream team, updated trial results on remdesivir, and a rough first quarter for big pharma stocks. In addition to our daily in-depth coverage of key regulatory events relating to the coronavirus pandemic, these three topics are among a selection of brief insights we’re bringing you on biopharma commercial activities.
Pluristem Therapeutics aims to start a multinational clinical trial of PLX cells for treating complications associated with COVID-19 while also helping severe patients recover from the disease under compassionate use programs in the US and Israel.
Recent collaborations involving Ridgeback, Themis, Junshi, Moleculin, Can-Fite, Pluristem and Beroni highlight the intense increase in research in how to treat or prevent COVID-19.
- Drug Delivery
- Gene Therapy, Cell Therapy
- Large Molecule